Abstract: Described herein is a composition for selectively etching a layer including a silicon germanium alloy (SiGe) in the presence of a silicon-containing layer, particularly a layer comprising a-Si, SiOx, SiON, SiN, or a combination thereof, the composition including: (a) an oxidizing agent, (b) an acid selected from an inorganic acid and an organic acid, (c) an etchant including a source of fluoride ions, (d) a polyvinylpyrrolidone (PVP), and (e) water.

Abstract: A soft and stretchable microelectrode array (sMEA) including a first circuit board having a first though hole; a second circuit board having a second through hole; a microelectrode array including a plurality of microelectrodes embedded in an elastomeric substrate, wherein the microelectrode array is disposed between the first and second printed circuit boards, and includes an exposed portion corresponding the first and second through holes; a plurality of contact pads formed on a top or bottom surface of the first printed circuit board and electrically connected to the plurality of microelectrodes; and a culture well mounted on the first printed circuit board and encompassing the first through hole. Further, the exposed portion of the microelectrode array includes a 3D pocket lined with stretched microelectrodes for electrically stimulating and recording signals from an organoid placed in the 3D pocket.

Abstract: Disclosed herein is a composition for selectively etching a layer including a silicon germanium alloy (SiGe) in the presence of a layer including silicon, the composition including: (a) 5 to 15% by weight of an oxidizing agent; (b) 5 to 20% by weight of an etchant comprising a source of fluoride ions; (c) 0.001 to 3% by weight of a first selectivity enhancer of formula S1 and (d) water.

Abstract: Peptides and pharmaceutical compositions comprising the same are described for use in the treatment and/or prevention of a disease caused by a virus affecting the respiratory tract, and in particular by an influenza virus or a coronavirus, among others. Additionally, a method and a kit for determining in vitro the resistance of an individual to being infected by a virus affecting the respiratory tract by determining the level of said peptides in the saliva of said individual is described.

Abstract: This invention refers to a probiotic composition consisting of the bacteria Lactobacillus rhamnosus, Lactobacillus casei and Bifidobacterium longum, preferably of the strains L. rhamnosus CECT8361, L. casei CECT9104 and B. longum CECT7347, and its use as an antioxidant. This composition is particularly useful in the treatment and/or prevention of damage, at the molecular level, caused by oxidative stress, preferably during high intensity physical exercise.

Abstract: A microencapsulated polyaddition catalyst comprises a capsule core, containing polyaddition catalyst, and an acrylic copolymer capsule shell, the acrylic copolymer comprising copolymerized units of an intermolecular anhydride of an ethylenically unsaturated C3-C12 carboxylic acid. The polyaddition catalyst is selected from acyclic tertiary amines, alicyclic tertiary amines, N-alkylimidazoles, phosphines and organic metal salts. It is suitable for catalysing the reaction of a polyol compound with a polyisocyanate compound. The polyaddition catalyst is released by a chemical stimulus, such as on contact with polyols or water, for example.

Abstract: The invention relates to a composition for selectively etching a layer comprising a silicon germanium alloy (SiGe) in the presence of a silicon-containing layer, particularly a layer comprising a-Si, SiOx, SiON, SiN, or a combination thereof, the composition comprising: (a) an oxidizing agent, (b) an acid selected from an inorganic acid and an organic acid, 10 (c) an etchant comprising a source of fluoride ions, (d) a polyvinylpyrrolidone (PVP), and (e) water.

Abstract: The present disclosure provides pharmaceutical compositions comprising 2-arylsulfonamido-N-arylacetamide derivatized Stat3 inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use.

Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.

Abstract: An order-picking installation for the order picking of items, in particular items transported in a hanging state, includes at least one supply station having a plurality of parallel supply locations, by which the items to be picked are supplied into the order-picking installation, and at least one dispatch station having a plurality of parallel dispatch locations, by which the picked items are discharged for dispatch, wherein at least one interim store is provided, for the order picking of the items, between the supply station and the dispatch station. The interim store includes a dynamic store for the interim storage of the items provided for order picking as well as a retrieval store, arranged downstream of the dynamic store, and intended for storing items which have been removed from the dynamic store and pre-sorted in the process, the dynamic store and the retrieval store arranged within a common circulatory conveyor.

Abstract: Provided is a process for the preparation of diosmin from hesperidin. The process involves the oxidation of acylated hesperidin with iodine or bromine in a C2-C4 carboxylic acid medium and subsequent treatment with an inorganic base to partially neutralize the acidic media. The process allows obtaining diosmin with low iodine or bromine content, avoiding the use of organic solvents.

Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases onused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.

Abstract: Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: An order-picking installation for the order picking of items, in particular items transported in a hanging state, includes at least one supply station having a plurality of parallel supply locations, by which the items to be picked are supplied into the order-picking installation, and at least one dispatch station having a plurality of parallel dispatch locations, by which the picked items are discharged for dispatch, wherein at least one interim store is provided, for the order picking of the items, between the supply station and the dispatch station. The interim store includes a dynamic store for the interim storage of the items provided for order picking as well as a retrieval store, arranged downstream of the dynamic store, and intended for storing items which have been removed from the dynamic store and pre-sorted in the process, the dynamic store and the retrieval store arranged within a common circulatory conveyor.

Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.

Abstract: A microencapsulated polyaddition catalyst comprises a capsule core, containing polyaddition catalyst, and an acrylic copolymer capsule shell, the acrylic copolymer comprising copolymerized units of an intermolecular anhydride of an ethylenically unsaturated C3-C12 carboxylic acid. The polyaddition catalyst is selected from acyclic tertiary amines, alicyclic tertiary amines, N-alkylimidazoles, phosphines and organic metal salts. It is suitable for catalysing the reaction of a polyol compound with a polyisocyanate compound. The polyaddition catalyst is released by a chemical stimulus, such as on contact with polyols or water, for example.

Abstract: The present disclosure provides pharmaceutical compositions comprising 2-arylsulfonamido-N-arylacetamide derivatized Stat3 inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use.

Abstract: Provided is a process for the preparation of diosmin from hesperidin. The process involves the oxidation of acylated hesperidin with iodine or bromine in a C2-C4 carboxylic acid medium and subsequent treatment with an inorganic base to partially neutralize the acidic media. The process allows obtaining diosmin with low iodine or bromine content, avoiding the use of organic solvents.

Abstract: Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: The present invention relates to a process for the preparation of diosmin from hesperidin. The process involves the oxidation of acylated hesperidin with iodine or bromine in a C2-C4 carboxylic acid medium and subsequent treatment with an inorganic base to partially neutralize the acidic media. The process allows obtaining diosmin with low iodine or bromine content, avoiding the use of organic solvents.